#AAIC21 – Aduhelm Shows Range of Benefits in EMERGE

#AAIC21 – Aduhelm Shows Range of Benefits in EMERGE

302348

#AAIC21 – Aduhelm Shows Range of Benefits in EMERGE

Treatment with Aduhelm (aducanumab) slows the clinical decline observed in in Alzheimer’s across a range of cognitive and functional measurements, according to a new analysis of data from a Phase 3 clinical trial. The results were presented at the Alzheimer’s Association International Conference (AAIC) 2021, held July 26–30 both virtually and in Denver, Colorado. The poster was titled, “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment with high-dose aducanumab in…

You must be logged in to read/download the full post.